Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MicroRNA as predictive biomarker of survival for stage IIIB colon cancer patients

Date

08 Oct 2016

Session

Poster Display

Presenters

Pan Li

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

P. Li1, Q. Ou2, G. Chen2, F.S. Oduncu1

Author affiliations

  • 1 Oncology, Klinikum der Universität München, 80336 - München/DE
  • 2 Colorectal Surgery, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
More

Resources

Abstract 2964

Background

The dismal outcome of stage IIIB colon cancer highlights the need for targeted therapies on the basis of effective predictive biomarkers, such as microRNA (miRNA).

Methods

Microarray was used to compare the miRNA expression profiles for 8 stage III B colon cancer patients with worse prognosis (metastases between 8 months and 18 months) and 8 cured stage III B colon cancer patients. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of the expression of targeted miRNAs was performed on tumor tissue of 98 patients with stage IIIB B colon cancer. A predictive model for 5-year disease-free survival (DFS) and overall survival (OS) was constructed using Kaplan–Meier analysis, logistic and Cox regression.

Results

miRNA-192-3p and miRNA-192-5p were down regulated in group with worse prognosis (P = 0.026 and P = 0.042 respectively). Patients with higher expression of miRNA-192-5p had higher 5-year DFS (84.21%) and OS (89.47%) than those with lower targeted miRNA expression (DFS 38.8%, HR: 3.74, 95% confidence interval (CI): 1.52-9.23, P: 0.04; OS 48.57%, HR: 5.01, 95%CI: 1.75-14.38, P: 0.03). Patients with higher expression MiRNA-192-3p did not statistically impact the survival in this setting (DFS 73.33%vs64.7%, HR:0.68, 95%CI: 0.31-1.52, P:0.35; OS 76.67%vs66.17%, HR: 0.62, 95% CI: 0.27-1.45, P: 0.27).

Conclusions

MiRNA-192-5p is highly predictive marker for stage III B colon cancer patients. MiRNA-192-3p had no predictive value in this setting

Clinical trial identification

Legal entity responsible for the study

P. Li, Q. Ou, G. Chen, F.S. Oduncu

Funding

Sun Yat-sen University

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings